Despite MAOs’ Claims, Recent Decision Doesn’t Imperil DOJ and Whistleblower Risk Adjustment Fraud Cases

Many MAOs have overplayed the significance of this decision.

On Sept. 7, in federal district court in Washington, D.C., in a case in which the Medicare Advantage Organizations (MAOs) in the UnitedHealth Group family of companies sued Alex Azar, the Secretary for the U.S. Department of Health and Human Services (HHS), a federal judge vacated a single Centers for Medicare & Medicaid Services (CMS) regulation – the 2014 “overpayment rule.”

In much of the reporting that has followed since, many of the MAOs have vastly overplayed the significance of this decision and its impact on the series of False Claims Act (FCA) cases currently being pursued against them by the Department of Justice and multiple whistleblowers in courts throughout the U.S. for alleged risk adjustment fraud. Contrary to the MAOs’ prognostications, however, the sky is not falling for FCA enforcement in Medicare, and the risk adjustment fraud cases remain very much intact.

First, a quick overview of the Medicare Advantage program and risk adjustment, to put this case in context. Medicare Advantage, or Medicare Part C, is a program through which individuals who are otherwise eligible for traditional Medicare can choose to be covered by a private insurer. CMS pays the private insurer premiums for taking risk off of the government’s hands. How much premium is paid to an MA plan is determined by a beneficiary’s demographics and his or her health status. For health status, certain diagnosis codes map to 79 hierarchical chronic conditions, or HCCs. Each HCC is a broad disease category that CMS has determined to be a pretty good predictor of future healthcare costs. The demographic factors, as well as the HCCs, have coefficients assigned to them. Those coefficients are added up to result in a risk score. The risk score is then multiplied by what an MA plan bids to cover a hypothetical, average-risk beneficiary, and that amount of money is paid to the MAO in monthly installments. For example, in 2014, the risk coefficient for an 81-year-old woman living in the community was .539; if she was also diagnosed with chronic hepatitis and congestive heart failure, the risk score would be increased by .251 and .368, respectively. The resulting risk score would be the sum of all of those, 1.158. If the plan bid $10,000, the MAO would be paid $11,580, in monthly installments, for insuring this woman.

The regulation at issue in this case, known as the 2014 overpayment rule, centers on what is defined as an overpayment, or any payment based on a diagnosis code submitted to the MA program not supported by an underlying medical record (and hence being invalid). Under the 2014 overpayment rule, an overpayment is “identified” if a MAO knew of the invalid code or should have determined through the exercise of reasonable diligence that it had received an overpayment for that code. The MAO must then return the overpayment within 60 days or else risk liability under the False Claims Act. This knowledge standard was found to be inconsistent with that of the Act, which requires actual knowledge or reckless disregard. By finding that MAOs acting based on mere negligence can violate the overpayment rule, the judge here held that a violation of the regulation cannot be an independent basis for FCA liability and must be struck down.

MAOs are attempting to use this decision as a barrier to liability in the False Claims Act cases in which they are alleged to have committed risk adjustment fraud. However, in the ruling here, the judge merely struck down a single, apparently flawed regulation that most of the existing Part C False Claims Act cases don’t rely on and barely make mention of. As the judge here noted, “UnitedHealth does not contend that Medicare Advantage insurers should be permitted knowingly or recklessly to bill CMS for erroneous diagnosis codes.” MAOs are still liable for knowing or reckless violations of the requirement to submit truthful and complete diagnostic data, and to correct erroneous submissions. MAOs and their attorneys who suggest otherwise are trying to turn the invalidation of a single regulation relating to the identification and timely return of overpayments into a broad license to commit plain and simple fraud.

 

Comment on this article

Facebook
Twitter
LinkedIn

Mary Inman, Esq.

Mary Inman is a partner and co-founder of Whistleblower Partners LLP, a law firm dedicated to representing whistleblowers under the various U.S. whistleblower reward programs. Mary and her colleagues have pioneered a series of successful whistleblower cases against prominent health insurers, hospitals, provider groups, and vendors under the False Claims Act alleging manipulation of the risk scores of Medicare Advantage patients. Mary is a recognized expert and frequent author, commentator, and speaker on frauds in the healthcare industry, particularly those exposed by whistleblowers. Mary is a member of the RACmonitor editorial board and a popular panelist on Monitor Monday.

Related Stories

Transparency in Coverage Final Rule

Transparency in Coverage Final Rule

The healthcare industry’s landscape shifted dramatically with the implementation of the Transparency in Coverage (TiC) Final Rule. For compliance professionals navigating this regulatory terrain, understanding

Read More

Leave a Reply

Please log in to your account to comment on this article.

Featured Webcasts

2026 IPPS Masterclass 3: Master MS-DRG Shifts and NTAPs

2026 IPPS Masterclass Day 3: MS-DRG Shifts and NTAPs

This third session in our 2026 IPPS Masterclass will feature a review of FY26 changes to the MS-DRG methodology and new technology add-on payments (NTAPs), presented by nationally recognized ICD-10 coding expert Christine Geiger, MA, RHIA, CCS, CRC, with bonus insights and analysis from Dr. James Kennedy.

August 14, 2025
2026 IPPS Masterclass Day 2: Master ICD-10-PCS Changes

2026 IPPS Masterclass Day 2: Master ICD-10-PCS Changes

This second session in our 2026 IPPS Masterclass will feature a review the FY26 changes to ICD-10-PCS codes. This information will be presented by nationally recognized ICD-10 coding expert Christine Geiger, MA, RHIA, CCS, CRC, with bonus insights and analysis from Dr. James Kennedy.

August 13, 2025
2026 IPPS Masterclass 1: Master ICD-10-CM Changes

2026 IPPS Masterclass Day 1: Master ICD-10-CM Changes

This first session in our 2026 IPPS Masterclass will feature an in-depth explanation of FY26 changes to ICD-10-CM codes and guidelines, CCs/MCCs, and revisions to the MCE, presented by presented by nationally recognized ICD-10 coding expert Christine Geiger, MA, RHIA, CCS, CRC, with bonus insights and analysis from Dr. James Kennedy.

August 12, 2025

Trending News

Featured Webcasts

The Two-Midnight Rule: New Challenges, Proven Strategies

The Two-Midnight Rule: New Challenges, Proven Strategies

RACmonitor is proud to welcome back Dr. Ronald Hirsch, one of his most requested webcasts. In this highly anticipated session, Dr. Hirsch will break down the complex Two Midnight Rule Medicare regulations, translating them into clear, actionable guidance. He’ll walk you through the basics of the rule, offer expert interpretation, and apply the rule to real-world clinical scenarios—so you leave with greater clarity, confidence, and the tools to ensure compliance.

June 19, 2025
Open Door Forum Webcast Series

Open Door Forum Webcast Series

Bring your questions and join the conversation during this open forum series, live every Wednesday at 10 a.m. EST from June 11–July 30. Hosted by Chuck Buck, these fast-paced 30-minute sessions connect you directly with top healthcare experts tackling today’s most urgent compliance and policy issues.

June 11, 2025
Open Door Forum: The Changing Face of Addiction: Coding, Compliance & Care

Open Door Forum: The Changing Face of Addiction: Coding, Compliance & Care

Substance abuse is everywhere. It’s a complicated diagnosis with wide-ranging implications well beyond acute care. The face of addiction continues to change so it’s important to remember not just the addict but the spectrum of extended victims and the other social determinants and legal ramifications. Join John K. Hall, MD, JD, MBA, FCLM, FRCPC, for a critical Q&A on navigating substance abuse in 2025.  Register today and be a part of the conversation!

July 16, 2025

Trending News

Happy National Doctor’s Day! Learn how to get a complimentary webcast on ‘Decoding Social Admissions’ as a token of our heartfelt appreciation! Click here to learn more →

CYBER WEEK IS HERE! Don’t miss your chance to get 20% off now until Dec. 2 with code CYBER24